IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 994 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
  Search
 
   Next article
   Previous article 
   Table of Contents
  
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
   [PDF Not available] *
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

 
  In this article
   Abstract
   Materials and Me...
   Results
   Comments
   References
   Article Tables

 Article Access Statistics
    Viewed11712    
    Printed120    
    Emailed3    
    PDF Downloaded0    
    Comments [Add]    
    Cited by others 1    

Recommend this journal

 


 
ORIGINAL CONTRIBUTIONS
Year : 1990  |  Volume : 56  |  Issue : 2  |  Page : 121-122

Treatment of vitiligo with psoralen




Correspondence Address:
P K Kar


Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

  Abstract 

The outcome of treatment in 120 cases of vitiligo receiving psoralen was analyzed. Forty patients were treated with topical psoralen, another 40 patients were given oral psoralen and the remaining 40 patients used, both oral and topical psoralens. Treatment was given once daily followed by sun exposure for 6 months. Fourteen cases using topical psoralen, 22 patients receiving oral psoralen lvmg and 24 patients receiving combined treatment showed partial repigmentation. Only 15% cases using oral psoralen alone showed complete repigmentation. Combined treatment was the most effective, leading to complete repigmrntation in 30% patients.


Keywords: Psoralen, Vitiligo


How to cite this article:
Kar P K, Snehi P S, Jha P K. Treatment of vitiligo with psoralen. Indian J Dermatol Venereol Leprol 1990;56:121-2

How to cite this URL:
Kar P K, Snehi P S, Jha P K. Treatment of vitiligo with psoralen. Indian J Dermatol Venereol Leprol [serial online] 1990 [cited 2019 Jan 22];56:121-2. Available from: http://www.ijdvl.com/text.asp?1990/56/2/121/3498


The reported incidence of vitiligo in various dermatological clinics in India varies from 3.5% to 4.3%. 12 Oral and topical psoralens have both been used with varying results for the treatment of vitiligo. 3 This trial was under­taken to compare the results of various modes of psoralen therapy on the repigmentation process in vitiligo.


  Materials and Methods Top


A total of 120 patients with vitiligo at quiescent stage were studied. Each patient was examined in detail. Routine laboratory investi­gations on urine, stools, hemoglobin and liver function tests were` undertaken in all the cases prior to starting the treatment.

Forty patients (Group 1) having less than 10 sq cm lesions were treated topically with 1 : 16 psoralen solution diluted with spirit. The dilu­tion was progressively decreased to a pure solution (0.25% psoralen) depending upon the reaction produced by the previous dilution. Another 40 patients (Group II) were given a single oral dose of psoralen, 0.6 mg/kg body wt (maximum 40 mg) daily. The remaining 40 patients (Group III) were given combined treatment consisting of topical application of psoralen lotion along with oral psoralen.

Fifteen minutes after the topical application and two hours after the oral intake of psoralen, the lesions were exposed to sun rays between 11.00 am to 2.00 pm for 1/2 minute per patch duting the first week and increased subsequently upto 2 minutes per patch. They were advised to wear optical dark glasses during the sun exposure and for 4 to 5 hours thereafter.

The patients were examined once in 15 days for 6 months to record the degree of repigmenta­tion. The patients who did not come regularly were excluded from this study.


  Results Top


The youngest patient was a 2-year-old girl and the oldest patient was 65 years. In 52 (43.2%) patients, the disease had started before the age of 20. Only 6 cases had a family history of vitiligo. All routine laboratory investigations were within normal limits except for the presence of intestinal worms in 14 (12%) cases. Exposed areas of the body were involved in 80 (66.6%) patients, front of legs in 60 (50%) patients, hands in 44 (36.6%), and face in 36 (30%) cases. Genitals were the least affected area, in 4 (3.3%) patients only. Circumscript type of vitiligo was seen in 96 (80%) cases, and segmen­tal type in 12 (10%) cases. Symmetrical lesions were found in 8 (6.6%) patients. Four (3.3%) patients had universal vitiligo. Twenty four (20%) had a single lesion, 28 (23.3%) had less than 10 lesions and 68 (56.6%) patients had more than 10 lesions.

In group I, 14 patients showed partial response to treatment, but none of them had complete repigmentation [Table - 1]. In group II, 22 patients showed partial response to the treatment and 6 patients showed complete repigmentation. In group III, 24 patients showed more than 50% repigmentation of the patches. In 12 patients repigmentation was complete. The remaining patients did not improve at all.


  Comments Top


In the aurvedic system of medicine Bavachee[4] (Psoralea corylifolia) seeds are used for the treatment of vitiligo. In Egypt, another plant Ammi majus Linn was employed. Psoralen has been used systemically for vitiligo for over two decades.[6]

In 45% of our cases, the initial response to treatment was erythema of the lesion and blisters in 25% cases. Majority (90%) of the patients in group I developed erythema and irritation on topical application of psoralen lotion even in 1:8 dilution. Eight patients developed blisters repeatedly and could not use even 1:16 dilution. The blisters were common (20%) in patients using topical psora­len lotion, and were not seen in any patient receiving systemic psoralen. If the blisters appeared, further applications of psoralen lotion were stopped and a soothing lotion or cream was prescribed. Later, the psoralen lotion was used in a more diluted form.

After 4-6 weeks of therapy, erythema would be followed by repigmentation. In 35% cases, the repigmentation was perifollicular in nature. A cream containing 10% paraminobenzoic acid was applied to the normal skin surro­unding the vitiligo patches particularly on the face before psoralen lotion was used. This helped to avoid disfiguring hyperpigmentation of the border areas.

Best results were obtained where psoralen was administered orally as well as applied topically followed by exposure to sun rays. In 60% of the patients with this modality of treatment repigmentation developed within 6 to 12 weeks. Only twelve (30%) patients showed complete repigmentation of the patches.

 
  References Top

1.Dutt AK and Mandal SS : A clinical study of 650 vitiiigo cases and their classification, Ind J Derma­tol, 1969; 14 : 103-107.  Back to cited text no. 1    
2.Gopinathan T : A study of the lesion of vitiligo, Arch Dermatol, 1965; 91 : 397-404.  Back to cited text no. 2    
3.Lerner AB, Denton CR and Fitzpatrick TB : Clinical experimental studies with 8-methoxy psoralen in vitiligo, J Invest Dermatol, 1959; 20 : 299-314.  Back to cited text no. 3    
4.Whitney WD : In Atherva veda sarnhita (Trans­lation and notes) Harvard oriental series, Vol 7, Lannman, Harvard University Press, Cambridge, 1905.  Back to cited text no. 4    
5.Fahmy IR and Abu-Shady H : Ammi maius Linn; Pharmacological study and isolation of crystal­line constituent, ammoidin, Quart J Pharm, 1947; 20 : 281-291.  Back to cited text no. 5    
6.Behl PN, Agarwal RS and Singh G : Aetiological studies in vitiiigo and therapeutic response to standard treatment, Ind J Dermatol, 1961; 6 101-104.  Back to cited text no. 6    


    Tables

[Table - 1]

This article has been cited by
1 Topical treatment in vitiligo and the potential uses of new drug delivery systems
Garg, B.J., Saraswat, A., Bhatia, A., Katare, O.P.
Indian Journal of Dermatology, Venereology and Leprology. 2010; 76(3): 231-238
[Pubmed]



 

Top
Print this article  Email this article
Previous article Next article

    

Online since 15th March '04
Published by Wolters Kluwer - Medknow